文献速递流行病学与生物统计临床试验与 GCP

成人急性非特异性腰背痛镇痛药物的比较有效性与安全性:系统综述与网络Meta分析

Comparative effectiveness and safety of analgesic medicines for adults with acute non-specific low back pain: systematic review and network meta-analysis.
PubMed 文献 · BMJ · 2023-03-22

该系统综述与网络Meta分析纳入98项随机对照试验(15134名参与者,49%为女性),评估镇痛药物治疗成人急性非特异性腰背痛的比较有效性与安全性。与安慰剂相比,托哌酮、醋氯芬酸联合替扎尼定、普瑞巴林等药物降低疼痛强度的证据置信度低或极低;曲马多、对乙酰氨基酚联合缓释曲马多、巴氯芬等药物增加不良事件的风险比有中至极低置信度。作者结论为比较有效性与安全性仍不确定,建议临床医生和患者谨慎使用镇痛药物。

要点

  • 与安慰剂相比,托哌酮降低疼痛强度的平均差为-26.1(95%CI -34.0至-18.2),证据置信度低或极低。
  • 与安慰剂相比,曲马多增加不良事件的风险比为2.6(95%CI 1.5至4.5),置信度中至极低。
  • 作者建议在高质量头对头随机对照试验发表前,临床医生和患者应谨慎使用镇痛药物管理急性非特异性腰背痛。

核心结论

  • 镇痛药物治疗成人急性非特异性腰背痛的比较有效性与安全性仍不确定。
  • 在高质量头对头随机对照试验发表前,建议临床医生和患者谨慎使用镇痛药物管理急性非特异性腰背痛。

研究设计与样本

  • 系统综述与网络Meta分析,检索Medline、PubMed、Embase、CINAHL、CENTRAL、ClinicalTrials.gov、clinicaltrialsregister.eu及WHO国际临床试验注册平台,从建库至2022年2月20日。
  • 纳入98项随机对照试验,共15134名参与者(49%为女性),涉及69种不同药物或组合。
  • 纳入标准为成人(≥18岁)急性非特异性腰背痛(病程少于六周),比较镇痛药物与另一镇痛药物、安慰剂或无治疗。
  • 由两名评价者独立筛选研究、提取数据并评估偏倚风险,采用随机效应网络Meta分析,并使用CINeMA方法评估置信度。

主要发现

  • 与安慰剂相比,托哌酮降低疼痛强度的平均差为-26.1(95%CI -34.0至-18.2),证据置信度低或极低。
  • 与安慰剂相比,醋氯芬酸联合替扎尼定降低疼痛强度的平均差为-26.1(95%CI -38.5至-13.6),证据置信度低或极低。
  • 与安慰剂相比,普瑞巴林降低疼痛强度的平均差为-24.7(95%CI -34.6至-14.7),证据置信度低或极低。
  • 与安慰剂相比,曲马多增加不良事件的风险比为2.6(95%CI 1.5至4.5),置信度中至极低。
  • 与安慰剂相比,对乙酰氨基酚联合缓释曲马多增加不良事件的风险比为2.4(95%CI 1.5至3.8),巴氯芬为2.3(95%CI 1.5至3.4),对乙酰氨基酚联合曲马多为2.1(95%CI 1.3至3.4),置信度中至极低。

关键数值与推荐

  • 主要结局为治疗结束时腰背痛强度(0-100量表)和安全性(治疗期间报告任何不良事件的参与者数)。
  • 次要结局为腰背特异性功能、严重不良事件和治疗中断。
  • 与安慰剂相比,托哌酮降低疼痛强度的平均差为-26.1(95%CI -34.0至-18.2),证据置信度低或极低。
  • 与安慰剂相比,曲马多增加不良事件的风险比为2.6(95%CI 1.5至4.5),置信度中至极低。

临床怎么用

  • 作者建议,在高质量头对头随机对照试验发表前,临床医生和患者应谨慎使用镇痛药物管理急性非特异性腰背痛。

局限性

  • 证据置信度低或极低,涉及托哌酮、醋氯芬酸联合替扎尼定、普瑞巴林等药物降低疼痛强度及多种药物间无差异的结论。
  • 不良事件增加的风险比置信度为中至极低。
  • 次要结局和药物类别次要分析的置信度也为中至低。
  • 作者指出需要更高质量的头对头随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the comparative effectiveness and safety of analgesic medicines for acute non-specific low back pain. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Medline, PubMed, Embase, CINAHL, CENTRAL, ClinicalTrials.gov, clinicialtrialsregister.eu, and World Health Organization's International Clinical Trials Registry Platform from database inception to 20 February 2022. ELIGIBILITY CRITERIA FOR STUDY SELECTION: Randomised controlled trials of analgesic medicines (eg, non-steroidal anti-inflammatory drugs, paracetamol, opioids, anti-convulsant drugs, skeletal muscle relaxants, or corticosteroids) compared with another analgesic medicine, placebo, or no treatment. Adults (≥18 years) who reported acute non-specific low back pain (for less than six weeks). DATA EXTRACTION AND SYNTHESIS: Primary outcomes were low back pain intensity (0-100 scale) at end of treatment and safety (number of participants who reported any adverse event during treatment). Secondary outcomes were low back specific function, serious adverse events, and discontinuation from treatment. Two reviewers independently identified studies, extracted data, and assessed risk of bias. A random effects network meta-analysis was done and confidence was evaluated by the Confidence in Network Meta-Analysis method. RESULTS: 98 randomised controlled trials (15 134 participants, 49% women) included 69 different medicines or combinations. Low or very low confidence was noted in evidence for reduced pain intensity after treatment with tolperisone (mean difference -26.1 (95% confidence intervals -34.0 to -18.2)), aceclofenac plus tizanidine (-26.1 (-38.5 to -13.6)), pregabalin (-24.7 (-34.6 to -14.7)), and 14 other medicines compared with placebo. Low or very low confidence was noted for no difference between the effects of several of these medicines. Increased adverse events had moderate to very low confidence with tramadol (risk ratio 2.6 (95% confidence interval 1.5 to 4.5)), paracetamol plus sustained release tramadol (2.4 (1.5 to 3.8)), baclofen (2.3 (1.5 to 3.4)), and paracetamol plus tramadol (2.1 (1.3 to 3.4)) compared with placebo. These medicines could increase the risk of adverse events compared with other medicines with moderate to low confidence. Moderate to low confidence was also noted for secondary outcomes and secondary analysis of medicine classes. CONCLUSIONS: The comparative effectiveness and safety of analgesic medicines for acute non-specific low back pain are uncertain. Until higher quality randomised controlled trials of head-to-head comparisons are published, clinicians and patients are recommended to take a cautious approach to manage acute non-specific low back pain with analgesic medicines. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42019145257.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Wewege MA, Bagg MK, Jones MD, et al. Comparative effectiveness and safety of analgesic medicines for adults with acute non-specific low back pain: systematic review and network meta-analysis. BMJ. 2023. PMID: 36948512. doi:10.1136/bmj-2022-072962

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。